DexCom, Inc. (DXCM)
| Market Cap | 43.38B |
| Revenue (ttm) | 2.03B |
| Net Income (ttm) | 514.00M |
| Shares Out | 96.30M |
| EPS (ttm) | 5.21 |
| PE Ratio | 88.36 |
| Forward PE | 200.00 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $459.92 |
| Previous Close | $448.58 |
| Change ($) | 11.34 |
| Change (%) | 2.53% |
| Day's Open | 448.56 |
| Day's Range | 447.60 - 461.00 |
| Day's Volume | 374,328 |
| 52-Week Range | 305.63 - 463.22 |
AEVA, BKD, CSGS, DXCM and EIG have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2021.
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recent regulatory clearance of Dexcom's (DXCM) real-time APIs is expected to aid diabetics as well as their care providers in accessing GCM data.
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #API--FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices
ONEM, BABA, DXCM, ORAN, and MTH have been added to the Zacks Rank #5 (Strong Sell) List on July 13, 2021
SAN DIEGO--(BUSINESS WIRE)-- #dxcm--Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time
DXCM, GP, PHR, RAD, and MAXR have been added to the Zacks Rank #5 (Strong Sell) List on July 6, 2021
SAN DIEGO--(BUSINESS WIRE)-- #ADA--Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association
CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes
Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the las...
Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.
Despite recent struggles, the investment thesis for this company remains strong.
BURNABY, British Columbia--(BUSINESS WIRE)---- $DXCM #cgm--Dexcom announces that people with diabetes may now be eligible for provincial coverage of the Dexcom G6 CGM System through BC PharmaCare.
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Looks to the Future of Continuous Glucose Monitoring
Analysts have provided the following ratings for DexCom (NASDAQ:DXCM) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2 0 0 Somewhat Bullish 0 2 1 0 Indifferent 1 0...
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Conference Presentation
The best is yet to come for these winning growth stocks.
No news was good news for the healthcare stock.
These three healthcare stocks have proven that growth and long-term trends are on their side.
For these two companies, the bull case remains intact.
While there have been rumors of AppleAAPL coming up with a CGM feature in its Apple Watch, the company hasn't confirmed it yet. That said, if Apple does come up with this feature, it will surely take ...
Investors were not pleased with the company's latest earnings report.
DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.
DexCom (DXCM) delivered earnings and revenue surprises of 6.45% and 4.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of DexCom (NASDAQ:DXCM) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 25.00% over the past year to $0.33, which beat the estim...
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2021 Financial Results
DexCom (DXCM) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Up over 250% in less than a year, what's behind the rise of this hot stock?
Steer clear of toxic stocks like MELI, HQY, DXCM, STNE and LVS to safeguard your portfolio.
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Each proved its worth during the coronavirus pandemic.
EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distributi...
Will future Tyvaso revenue growth push United Therapeutics to new heights?
SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time.
Financial media can often divert your attention away from the best investments.
SAN DIEGO--(BUSINESS WIRE)---- $DXCM--Dexcom Promotes Jereme Sylvain to Chief Financial Officer
Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.
Toxic stocks are vulnerable to external shocks and are burdened with huge debts. It's important to ensure that you safeguard your portfolio from such stocks.
When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can hel...
Toxic stocks usually carry huge debt load and are vulnerable to external shocks. They should be timely discarded from one's portfolio to avoid wealth erosion.
DexCom Inc. (NASDAQ:DXCM) said it expects 2021 revenue to increase between 15% and 20% to more than $2.2 billion as it extends its diabetes care business into two new areas of the disease, prediabetes a...
If the market plunges, picking up these fast-paced companies at a discount would be a wise move.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations
DexCom CEO says Super Bowl ad sparked high interest in its glucose tracker
DexCom CEO Kevin Sayer said the company had 5 times more media impressions in one day than it had all last year after airing Super Bowl spot featuring Nick Jonas, helping to get the message out about it...
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.
DexCom (DXCM) delivered earnings and revenue surprises of 0.00% and 1.88%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LL... [Read more...]
| Industry Diagnostics & Research | IPO Date Apr 14, 2005 |
| CEO Kevin Sayer | Employees 5,500 |
| Stock Exchange NASDAQ | Ticker Symbol DXCM |
Financial Performance
In 2020, DexCom's revenue was $1.93 billion, an increase of 30.54% compared to the previous year's $1.48 billion. Earnings were $493.60 million, an increase of 388.23%.
Analyst Forecasts
According to 21 analysts, the average rating for DexCom stock is "Buy." The 12-month stock price forecast is 477.95, which is an increase of 3.92% from the latest price.